EUROPEAN COMMISSION HEALTH & FOOD SAFETY. Directorate G Veterinary and International affairs. Unit G2- Animal health

Similar documents
Role of an OIE Reference Laboratory Trichinellosis. Edoardo Pozio Istituto Superiore di Sanità Rome, Italy

OIE Procedure for Registration of Diagnostic Kits. Abstract sheet

18 th WAVLD Congress Development and Validation of tuberculosis real-time PCR kit

Minutes of the 1 st meeting of the Working Group on Tb test Brussels, 15 February 2012 EFSA / Unit /AHAW. Agreed by the WG on 22 February 2012

OIE Reference Laboratory Reports Activities

IGRA: Diagnosing TB in the Twenty-First Century with. Peter Barnes, MD

OIE Reference Laboratory Reports Activities

Making More Efficient Use of Biospecimens. ISBER Contributions and Initiatives

GMO Technology Conference

OIE Standard on principles and methods of validation of diagnostic assays for infectious diseases

OIE Reference Laboratory Reports Activities

OIE Reference Laboratory Reports Activities

Follow-up Reporting. Format for Reporting on Follow-up Action Recommendations Action Agreed Action Taken? Comment/explanation Recommendation 1

Animal Health Laboratories Ltd,

OIE Reference Laboratory Reports Activities

Independent Milk Laboratories Ltd.

OIE Reference Laboratory Reports Activities

International Seed Testing Association

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs

CONTENT 1. INTRODUCTION 2. METHODS 3. RESULTS Quality assurance system Staff personnel and analytical activities Laboratory methods

Update on activities in ISO and CEN. Kirsten Mooijman

Detailed Training programme Day 1

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

Annual report on Activities Performed by the UK NRL for GMOs in Feed and Food

Fifth GF-TADs for Europe Steering Committee meeting (RSC5) FAO assistance to prevent and control African Swine Fever( ASF)

Module C Veterinary Public Health Hygienic Production of Food (C VPH.2)

Assessing quality-assured diagnoses made by TB laboratories

Update on Recast of IVD Directive

Pharmabiotics: a Regulatory Hurdle in Europe

EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008

The European Medical Technology Industry. in figures / 2018

Residues of Pesticides in foodstuffs of animal origin : Monitoring programs in France. Jean-Pierre ORAND French Ministry of Agriculture

Due diligence in the European medical devices industry

Animal identification and traceability in the European Union and international trade

Validation of ante mortem TB tests in Camelids

OIE Reference Laboratory Reports Activities

The definitions given below have been selected and restricted to those that are likely to be useful to users of this OIE Terrestrial Manual.

LABORATORY TRAINING LOGBOOK

OIE Reference Laboratory Reports Activities

INDUSTRY S VIEW ON THE FUTURE OF IN VITRO DIAGNOSTIC (IVD) LEGISLATION IN EUROPE. May 2013 SPECIAL REPRINT. By Jesús Rueda Rodríguez, EDMA

Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant.

The FP7 EU Project The Disease Control Tools (DISCONTOOLS, the contribution of an Expert Group on E.

Guideline on requirements for the production and control of immunological veterinary medicinal products

Animal Identification, animal breeding and international trade- the new EU Regulation on Zootechnics. Sergio Pavón

I EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

i) Wild animals: Those animals that do not live under human supervision or control and do not have their phenotype selected by humans.

Code and manual. Aquatic animals

HSV-2 therapeutic vaccine program. Subunit vaccine candidates

OIE Reference Laboratory Reports Activities

European Directorate for the Quality of Medicines & HealthCare (EDQM)

OVERVIEW OF THE RESULTS OF A SERIES OF MISSIONS CARRIED OUT DURING TO EVALUATE CONTROLS OVER PIG MEAT PRODUCTION IN MEMBER STATES

Market surveillance of medical devices

IGRAs for Serial Testing of Healthcare Workers

Selection and use of Ebola in vitro diagnostic (IVD) assays

Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None

progress in GMO analysis and presentation of the Compendium of validated reference methods

A2LA. R231 Specific Requirements: Threat Agent Testing Laboratory Accreditation Program. December 6, 2017

REGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

Evaluation of Different PCR-based Techniques in Diagnosis of Bovine Tuberculosis in Infected Cattle Lymph Nodes

Instrument specifications Technology Software Host interfaces Printer interfaces Data Station Physical dimensions Weight Certifications

Long-Range Research Initiative Global Research Strategy. 21st Century Approaches to Risk Sciences

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE

Our Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service.

Review of requirements for immunological medicinal products and their evolution since the start of Community legislation on medicines

Computerised Infectious Disease Reporting (CIDR)

UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS

A new era in access to high performance diagnostics?

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Implementation of EU Directives concerning Energy Efficiency & the utilisation of RES in Spain, focusing on the PV Energy experience

IVD Regulation 2017/746

ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure

Ready or Not: The New Medical Device Regulations Are Here!

The Role of a Notified Body in Defining Risk Assessment for a Recombinant Protein Used in a Medical Device Case Study

Update on the IVDR. Sue Spencer

Interferon Gamma Release Assays (IGRAs) for the Diagnosis of Latent Tuberculosis Infection. Conflict of interest statement.

Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS

(Non-legislative acts) REGULATIONS

Isolation of Viral RNA, Viral DNA and Bacterial DNA from Animal Samples

HOW TO APPLY FOR MEDICAL DEVICE REGISTRATION UNDER MEDICAL DEVICE ACT 2012 (ACT 737)

2 nd Phase activities of the TDG Roadmap and Invitation for the nomination of EUDG members. Publication of the Inland TDG Risk Management framework

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL GUIDELINES ON MEDICAL DEVICES

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations

RODENT COLONY HEALTH MONITORING

OIE Reference Laboratory Reports Activities

Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation

Veterinary Medicines Legislation and Maximum Residue Limits in the EU

Validation of ante mortem TB tests in Camelids

Diagnostic methods for Lumpy skin disease virus LSD Expert: Dr Eeva Tuppurainen

View on Usability of EFSA Outputs. Annette Toft, chair of Copa and Cogeca s working party on Food 30 May 2017, EFSA Stakeholders Forum

OIE Reference Laboratory Reports Activities

Audits PDO/PGI/TSG Examples of Good Practices. Johannes Kern DG SANTE/FVO Unit F4.3

EA MULTILATERAL AGREEMENT Facilitating cross border trade with reliable goods and services

Transcription:

EU-RL for Bovine Tuberculosis Ref. Ares(2016)855831 VISAVET v4-18/02/2016 EUROPEAN COMMISSION HEALTH & FOOD SAFETY Directorate G Veterinary and International affairs Unit G2- Animal health EUROPEAN UNION REFERENCE LABORATORY (EU-RL) FOR BOVINE TUBERCULOSIS WORK PROGRAMME 2016-2017 Version 4 VISAVET Health Surveillance Centre Universidad Complutense de Madrid Contact person: Dr. Lucía de Juan (EU-RL Director) Address: VISAVET Health Surveillance Centre Universidad Complutense de Madrid Avda. Puerta de Hierro s/n 28040 Madrid, Spain Phone number: +34 913943910 Fax number: +34 913943795 E-mail address: dejuan@visavet.ucm.es 1

Table of contents A. MAIN ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2016-2017.... 4 1. Immunological diagnosis of bovine tuberculosis....4 1.1. Single Intradermal Tuberculin test....4 1.2. Use of IFN-γ in the EU....4 2. Setting up an alternative protocol for bacteriological culture: molecular detection of Mycobacterium tuberculosis complex in animal tissues....5 3. Molecular database....5 4. Comparative tests....6 5. Missions....6 6. Training of personnel...7 7. Workshop....7 8. Expert Meeting....8 B. OTHER ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2016-2017.... 8 1. Preparation, control and supply of laboratory material (including in house spoligotyping membranes) and protocols....8 2. Collection of representative samples (tissue samples, strains, DNA, serum/plasma)....8 3. Isolation, identification and typing of mycobacteria....8 4. World Wide Web page update....8 5. Technical assistance to the Commission and NRLs and participation with EFSA and international organizations (bovine tuberculosis subgroup of the Task Force, OIE)....8 7. Keeping abreast of developments (papers, conferences, training courses, reports, legislation, etc.) and research activities (collaboration with NRLs, participation in research projects, etc.)....9 8. Technical and financial management of the activities included in the work programme....9 2

The purpose of the work programme is to cover the objectives (general, specific and operational) defined in the Annex to the Commission Implementing Decision establishing the work programme for the years 2016 and 2017 on financial contribution to the European Union reference laboratories, taking into account the responsibilities and tasks defined in the Annex II to Commission Regulation (EC) No 415/2013 regarding the EU-RL for Bovine Tuberculosis: 1. To coordinate, in consultation with the Commission, the methods employed in the Member States for diagnosing bovine tuberculosis. 2. To facilitate the harmonization of techniques throughout the Union, in particular specifying standard test methodologies. 3. To organize workshops for the benefit of national reference laboratories as agreed in the work programme and estimated budget referred to in Article 2 of Implementing Regulation (EU) No 926/2011, including training of experts from the Member States and, as appropriate, from third countries, in new analytical methodologies. 4. To provide technical assistance to the Commission and, upon its request, to participate in international forums relating to the diagnostic of bovine tuberculosis, concerning in particular the standardization of analytical methods and their implementation. 5. To perform research activities and, whenever possible, coordinate research activities directed towards the improved control and eradication of bovine tuberculosis. 3

A. MAIN ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2016-2017. 1. Immunological diagnosis of bovine tuberculosis. 1.1. Single Intradermal Tuberculin test. Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network. Description: One of the main activities for the EU-RL for Bovine Tuberculosis is to test the biological potency of the Purified Protein Derivatives (PPD or tuberculin) in sensitized guinea pigs since they are the reagents for the official in vivo (skin test) and in vitro (IFNγ) diagnostic assays based on cell-mediated immune response for the diagnosis of bovine tuberculosis. Nowadays there are several PPD manufactures all over Europe and the potency testing protocols between NRLs are not harmonized. Moreover, the technical capacity to perform the skin test must be guaranteed trough accreditation of the protocol. Objectives: A harmonized protocol for guinea testing will be set up in the 2015 EU-RL workshop and the NRLs will have to set it up in their laboratories in order to report any deviation or possible modification to the defined protocol. Moreover, the EU-RL will start the process to validate the skin test protocol in the field. Expected outputs: a) Standard protocol for biological potency testing in guinea pigs to be set up in the NRLs; b) Skin test protocol accreditation. 1.2. Use of IFN-γ in the EU. Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network. Description: The IFN-γ test is used together with the skin test to detect a higher number of infected animals. During 2012, a Scientific Opinion on the use of gamma interferon test for the diagnosis of bovine tuberculosis [EFSA Journal 2012;10(12):2975] was published and consequently, the EU-RL is working to produce a harmonized protocol with a recommendation to be used as an alternative to the tuberculin skin test for the establishment and maintenance of an officially tuberculosis-free herd status and for certification for intra-union trade in bovine animals. In this sense, the EU-RL together with other NRLs (France, Italy, United Kingdom and Ireland) has produced an exhaustive working document that compiles the scientific information regarding the IFN protocol. This protocol will be presented to all the NRLs to reach consensus regarding harmonization of critical steps (bovine PPD concentration, origin PPDs, time between collection and stimulation in the laboratory, duplicates, mitogen, plasma conservation and interpretation criteria and cut-off point). 4

Objectives: To reach consensus regarding the harmonization IFN protocol among NRLs and to compile data about the implementation of the recommended protocol in the Member States. Expected outputs: To define the harmonized IFN-γ protocol between all the NRLs. 2. Setting up an alternative protocol for bacteriological culture: molecular detection of Mycobacterium tuberculosis complex in animal tissues. Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network. Description: During the last two years, the EU-RL has developed an extraction protocol combined to a Real Time PCR assay for the detection of members of the Mycobacterium tuberculosis complex (MTBC) in animal tissues. This protocol, when validated could replace the bacteriological culture. Objectives: Work will be performed to increase the sensitivity of the direct extraction technique focused in the homogenization step (mechanical disruption of the sample). Moreover, the optimized direct extraction protocol will be compared with the culture protocol (including the new disruption step). A set of samples will be analyzed in parallel to be able to perform a Bayesian study. The main objective is the identification of mycobacteria but this new step could also enhance the molecular characterization performed directly from clinical samples, since the current protocol does not allow typing of all strains. Finally, a protocol will be sent to the European Commission for consideration as an official testing for bovine tuberculosis. Expected outputs: To create a robust and efficient molecular protocol for the detection and molecular characterization of members of the MTBC in animal tissues. 3. Molecular database. Operational objective 1 and 3: To ensure the development and use of high quality analytical methods across the EU-RL network; and to ensure the availability of scientific and technical assistance provided by the EU-RLs. Description: DVR-spoligotyping is still considered as the routine molecular characterization protocol for members of the MTBC. Two main databases are available: the SITVIT Database (Public Health, Demay et al. 2012) and the mbovis.org (Animal Health, Smith et al. 2012). In 2015, the mbovis.org database has been migrated to the VISAVET server. During 2016-2017, a specific European database will be designed (mboviseu.org) within the mbovis.org. For this objective, the EU-RL will contact the NRLs to collect all the characterization data regarding M. bovis/m. caprae isolates in Europe. This will allow the registration of the isolates identified in each Member State and 5

therefore facilitate future epidemiological studies between Member States. The last step (scheduled 2017-2018) will be to include the M. bovis/m. caprae isolates identified in human through the Public Health NRLs. Objectives: a) To maintain the mbovis.org database in the VISAVET server (EU-RL website); and b) to create a specific European database (mboviseu.org) to generate epidemiological data between European countries. Expected outputs: Maintenance of a molecular database (workdwide-mbovis.org and European-mbovisEU.org) to guarantee the standardization of nomenclature for DVRspoligotyping profiles allowing epidemiological studies. 4. Comparative tests. Operational objective 1 and 2: To ensure the development and use of high quality analytical methods across the EU-RL network; and to maintain appropriate level of proficiency testing ensuring efficiency of control analysis methods. Description: The EU-RL has the responsibility of organising periodical comparative tests of diagnostic procedures and operating laboratory proficiency test of NRLs to ensure high quality and harmonization of laboratory testing of animal diseases across the European Union. The ring trials organized by the EU-RL are focused in three main topics: 1) Bacteriological culture and direct extraction; 2) Identification and molecular characterization; and 3) Immunological diagnosis. The EU-RL will organize two ring trials a year for 2016 and 2017. The topics will be discussed with the NRLs in the workshop that will be held in Madrid at the end of 2015, although the EU-RL will propose the following ring trials: bacteriological culture & direct extraction, histopathological diagnosis, detection of IFN-γ and PPDs potency testing. Objectives: To organize two ring trials a year for all the NRLs. The proposed comparative tests will be bacteriological culture & direct extraction, histopathological diagnosis, detection of IFN-γ and PPDs potency testing. Expected outputs: To ensure high quality and harmonization of laboratory protocols of bovine tuberculosis in European Member States. 5. Missions. Operational objective 1, 2 and 3: To ensure the development and use of high quality proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs. Description: If requested by the EC or under specific circumstances, the EU-RL staff will visit the European Commission or NRLs. Moreover, to perform the studies regarding tuberculosis testing (in vivo and in vitro) the EU-RL staff visits: a) cattle farms to collect 6

blood samples for the EU-RL samples bank; b) slaughterhouses to collect tissue samples (lymph nodes and organs); and c) CVO offices to discuss sampling of cattle farms. Another objective of the EU-RL is to keep abreast of developments mainly in diagnosis and epidemiology of tuberculosis and therefore the EU-RL staff attend congresses, workshops, training courses and they are updated through reports from experts, legislation, scientific papers, etc. Objectives: a) To assist the EC/NRLs; b) To collect biological samples (farm/slaughterhouse); and c) To attend conferences and training courses. Expected outputs: a) Technical advice/collaboration with EC/NRLs; b) Collection of samples for field studies included in the WP; and c) Scientific training of the EU-RL staff. 6. Training of personnel Operational objective 1, 2 and 3: To ensure the development and use of high quality proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs. Description: As included in the Annex II of the Commission Regulation (EC) No 415/2013, the EU-RL must train experts from the Member States. These training mobilities are focused in laboratory protocols (bacteriological culture, direct extraction, identification by PCR, molecular characterization, detection of IFN-γ) as well as accreditation process and the workflow in a Biosafety Laboratory Level 3. Objectives: Short visits (2-3 days) for two National Reference Laboratories per year to allow the establishment of laboratory protocols and techniques in their laboratory of origin. The trainee will present the activities of his/her NRL to the EU-RL and will submit a brief report after the visit. Expected outputs: Training of NRL staff in mycobacteria protocols (culture, direct extraction, PCR, DVR-spoligotyping, MIRU-VNTR, IFN-γ test) and accreditation system. 7. Workshop. Operational objective 1, 2 and 3: To ensure the development and use of high quality proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs. Description: A workshop is an annual meeting for information and coordination for all National Reference Laboratories. Objectives: To organize a workshop in 2017 with all the NRLs to present the information regarding the activities performed by the EU-RL in the previous years and to find out the priorities and necessities regarding bovine tuberculosis diagnosis of the different NRLs. 7

Expected outputs: Annual meeting in 2017 to share information regarding EU-RL activities with the NRLs. 8. Expert Meeting. Operational objective 1, 2 and 3: To ensure the development and use of high quality proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs. Description: The Guinea Pig Potency Test (GPPT) is the protocol defined in the legislation for determination of the biological potency of the PPDs. Determination of the biological potency is relevant for the correct performance of the skin test protocol in bovine tuberculosis diagnosis. In this sense, Dr. Bakker has a broad experience in this assay since he has been in charge for several years in the Dutch NRL. The EU-RL, considers his participation important to reach a general consensus regarding not only the protocol but also the interpretation of the results. Objectives: To organize a meeting with an expert in Guinea Pig Potency Test (GPPT). Expected outputs: Standard protocol and interpretation criteria for biological potency testing in guinea pigs. B. OTHER ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2016-2017. Operational objective 1, 2, 3 and 4: To ensure the development and use of high quality proficiency testing ensuring efficiency of control analysis methods; to ensure the availability of scientific and technical assistance provided by the EU-RLs; and to ensure a sound and efficient management of EU-RL funding cycle. The following tasks will remain permanent activities of the EU-RL for 2016-2017. 1. Preparation, control and supply of laboratory material (including in house spoligotyping membranes) and protocols. 2. Collection of representative samples (tissue samples, strains, DNA, serum/plasma). 3. Isolation, identification and typing of mycobacteria. 4. World Wide Web page update. 5. Technical assistance to the Commission and NRLs and participation with EFSA and international organizations (bovine tuberculosis subgroup of the Task Force, OIE). 6. Dissemination (presentations at international and national congresses or conferences, and publication in international and national journals). 8

7. Keeping abreast of developments (papers, conferences, training courses, reports, legislation, etc.) and research activities (collaboration with NRLs, participation in research projects, etc.). 8. Technical and financial management of the activities included in the work programme. 9